Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord BiotechBOM:543960 +0.67%68 Interest Coverage is 1,178.42 as of Mar. 2026, which is 323% above its 10-year median of 278.45. GuruFocus rates BOM:543960 with a GF Score™ of 68/100 and a GF Value™ of ₹1,666.31 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 376 Biotechnology companies, Concord Biotech ranks better than 60.9% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Concord Biotech's
Operating Income
for the
three
months ended in Mar. 2026 was ₹990 Mil. Concord Biotech's Interest Expense for the
three
months ended in Mar. 2026 was ₹-1 Mil.
Concord Biotech's interest coverage for the quarter that ended in Mar. 2026 was 1,178.42.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Concord Biotech Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Concord Biotech's Interest Coverage or its related term are showing as below:
BOM:543960'
s Interest Coverage Range Over the Past 10 Years
Min: 43.06 Med: 278.45 Max: 1080.98
Current: 1034.4
BOM:543960's Interest Coverage is ranked better than 60.9% of 376
companies
in the Biotechnology industry
Industry Median: 106.135
vs BOM:543960: 1034.40
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Concord Biotech Interest Coverage Related Terms
Concord Biotech Interest Coverage Historical Data
* Premium members only.
The historical data trend for Concord Biotech's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:543960 vs VRTX, REGN, RVMD: Interest Coverage Comparison
For the Biotechnology subindustry, Concord Biotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Concord Biotech's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Biotech (BOM:543960) has a Interest Coverage of 1,178.42 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Concord Biotech and its competitors. This is 323% above median its historical median of 278.45. Over the past decade, Concord Biotech's Interest Coverage has ranged from 43.06 to 1,080.98. According to the industry distribution chart, Concord Biotech ranks #147 out of 376 companies in the Biotechnology industry, placing it in the top 39.1%.
Is Concord Biotech's Interest Coverage too high?
Concord Biotech's current Interest Coverage of 1,178.42 is 323% above median its 10-year median of 278.45. Over the past 10 years, this metric has ranged from a low of 43.06 to a high of 1,080.98. The Biotechnology industry median Interest Coverage is 106.14. Concord Biotech's value of 1,178.42 is 1010.3% above this industry median. Based on the distribution chart, Concord Biotech ranks #147 out of 376 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Concord Biotech has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #147 out of 376 companies for Interest Coverage. This puts Concord Biotech in the upper half of its industry. The industry median Interest Coverage is 106.14. Concord Biotech's value of 1,178.42 is 1010.3% above this benchmark. Historically, Concord Biotech's own Interest Coverage has ranged from 43.06 to 1,080.98 over the past decade. While the company's 10-year median is 278.45 vs. the industry median of 106.14, Concord Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.14, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Biotech's current Interest Coverage of 1,178.42 is 1010.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Concord Biotech and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Biotech's current Interest Coverage is 1,178.42, which is 323% above median its own 10-year median of 278.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,666.31, compared to a current price of ₹1,257.00 — trading 24.6% below its estimated fair value. The current Interest Coverage is 1,178.42, which is 323% above median its 10-year median of 278.45 and 1010.3% above the Biotechnology industry median of 106.14. Concord Biotech's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current Interest Coverage is 1,178.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,257.00 is trading 24.6% below its estimated GF Value™ of ₹1,666.31.
GuruFocus considers Concord Biotech to be Modestly Undervalued.
Key valuation signals for BOM:543960:
Interest Coverage: 1,178.42 (323% above median its 10-year median of 278.45)
GF Value™: ₹1,666.31 vs. price of ₹1,257.00 (24.6% below fair value)
Industry Position: 1010.3% above the Biotechnology median (#147 of 376)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
68GF Score
Get the complete analysis for BOM:543960
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
